FIELD: medicine.
SUBSTANCE: invention relates to medicine and can be used in therapy, cardiology, angiology, cardiac surgery. In the blood serum of patients with acute decompensation of ischemic CHF with LV systolic dysfunction, the content of the serum biomarker LIGHT is determined using multiplex analysis. When detecting in patients with acute decompensation of ischemic CHF with LV systolic dysfunction, the LIGHT level of 30.05 ng/ml or more predicts the risk of adverse cardiovascular events.
EFFECT: method provides a non-invasive method to identify a priority group of patients with acute decompensation of ischemic CHF with systolic LV dysfunction for hospital and dispensary observation with the organization of effective targeted measures aimed at preventing the development of adverse cardiovascular events and preventing high premature mortality in these patients.
1 cl, 1 dwg, 4 tbl, 3 ex
